We are a globally leading end-to-end generative AI-driven biotech company in terms of AIDD pipeline progress, with a mission to accelerate drug discovery and development by leveraging our rapidly evolving, proprietary Pharma.AI platform across biology, chemistry and clinical development. Our generative AI platform helps us to rapidly and efficiently advance our fully self-generated AIDD pipeline primarily composed of novel drug candidates.
Innoviva Specialty Therapeutics
Innoviva Specialty Therapeutics, a subsidiary of Innoviva, Inc., is a biotechnology company focused on developing and commercializing innovative therapies in critical care and infectious disease. The company’s commercial portfolio include the first and only antibiotic developed specifically to treat Acinetobacter pathogens in adults; a vasopressor indicated to increase blood pressure in adults with septic or other distributive shock; and a broad-spectrum antibiotic to treat complicated intra-abdominal infections in adults. For more information, visit www.innovivaspecialtytherapeutics.com.
INFORS HT, USA
INFORS HT, a Swiss-based company with U.S. manufacturing in Maryland, brings 60 years of expertise to bioprocessing research and development. We specialize in bioreactors, incubator shakers, and bioprocess software, offering scalable solutions for microbial and animal cell cultures. By understanding the evolving needs of the market and maintaining strong connections with our clients, we ensure that our products and services are not only advanced but also perfectly tailor to real-world applications. | INFORS HT, a Swiss-based company with U.S. manufacturing in Maryland, brings 60 years of expertise to bioprocessing research and development. We specialize in bioreactors, incubator shakers, and software, offering scalable solutions for microbial and animal cell cultures. By understanding the evolving needs of the market and maintaining strong connections with our clients, we ensure that our products and services are not only advanced but also perfectly tailor to real-world applications.
Incyte Corporation
Incyte is a global biopharmaceutical company that is focused on finding solutions for serious unmet medical needs through the discovery, development and commercialization of novel medicines. Since 2002 Incyte has remained committed to the relentless pursuit of science that can improve the lives of patients, make a difference in healthcare and build sustainable value for our stakeholders. Incyte’s unique expertise in medicinal chemistry and biology have enabled us to create a diversified pipeline of clinical candidates, the majority of which were discovered by Incyte scientists. We are advancing a growing portfolio of medicines across Oncology and Inflammation & Autoimmunity. Headquartered in Wilmington, Delaware, Incyte has operations in North America, Europe and Asia. For more information, visit Incyte.com and follow @Incyte.
Immunocore
Immunocore is a commercial-stage biotechnology company that discovered, developed and commercialized the world’s first approved T cell receptor (TCR) therapy. Our mission is to radically improve outcomes for patients with cancer, infectious diseases, and autoimmune diseases, by pioneering and delivering transformative immunomodulating medicines. Built on our proprietary ImmTAX technology, we have a pipeline of investigational bispecific TCR therapies across a broad range of diseases, including multiple types of cancers, HIV, type 1 diabetes, and other autoimmune diseases. CM-US–2600011
Imagene AI
Imagene AI is a pioneer in multimodal foundation models for precision medicine, advancing translational research and clinical development. Our Cross-Modality Intelligence Engine, delivered through the OI Suite, integrates real-world data including histopathology images, multi-omic data, longitudinal clinical records to derive meaningful, biologically grounded insights, generate and validate biomarker hypotheses, and increase predictive power in low-data settings. We make every trial more responsive, every insight more actionable, and every patient journey more personalized. Founded in 2020 and backed by leading investors including Larry Ellison, and advised by world-leading oncologists on our Scientific Advisory Board, Imagene AI has been recognized with the Pharmaceutical Technology Excellence Award and the Digital Health Innovation Award as one of the Top 25 Healthcare AI Companies of 2025.
Hyundai Bioscience
HYUNDAI BIOSCIENCE develops and manufactures innovative anticancer therapeutics leveraging proprietary drug delivery system (DDS) technologies to enhance bioavailability and improve tumor-targeting selectivity. Our commitment to addressing unmet medical needs drives us to continuously refine our platform technologies and explore new treatment paradigms for cancer patients worldwide. (Pipeline Overview) POLYTAXEL®: A docetaxel-based, pain-free anticancer therapy designed to reduce treatment-associated discomfort. Currently in the clinical stage, with Phase 1 IND submitted in Korea. Penetrium™: An oral niclosamide-based therapy targeting ECM(extracellular matrix), aimed at eradicating resistant tumor cell populations. Undergoing preclinical development. OTX-M™: A taxane-based oral metronomic therapy intended to maintain sustained anticancer activity with potentially reduced toxicity. Also in preclinical development. By integrating cutting-edge DDS technologies with robust clinical and preclinical strategies, HYUNDAI BIOSCIENCE strives to advance the future of cancer treatment and improve patient outcomes.
Hitchem
Hitchem is a cutting-edge small molecule drug discovery company with over six years of experience in identifying hits for novel targets. By integrating advanced dry and wet lab capabilities, we accelerate drug discovery and development. Our dry lab Computer-Aided Drug Design, cheminformatics, and data-driven methodologies to design innovative molecular solutions, while our wet lab specializes in chemistry services, including molecular glue libraries for protein degradation and cyclic peptide libraries for protein-protein interaction inhibition.
HiComp Microtech
Established in 2014, HiComp Microtech is a leading original design manufacturer (ODM) specializing in advanced microfluidic products and laboratory consumables. Our ISO-certified and FDA-registered facilities span 100,000 sq. ft., including approximately 40,000 sq. ft. of high-standard cleanroom space. We provide precision, efficiency, and reliability from prototyping through volume production, serving renowned pharmaceutical and clinical diagnostic companies globally. With a proven track record, HiComp has successfully completed over 100 commercialized projects. | Hicomp Microtech is a leading original design manufacturer of cutting-edge microfluidics products and laboratory consumables. Our innovative solutions are designed to help researchers and engineers achieve greater accuracy, efficiency, and reliability in their projects from prototype to volume production. With a focus on quality, performance, and affordability, we’re committed to delivering products that meet the highest industry standards. From microfluidic chips to microplates and more, our products are designed to empower scientists to make groundbreaking discoveries and improve the world around us. Choose Hicomp Microtech for your laboratory needs and experience the future of microfluidics today. | Established in 2014, HiComp Microtech is a leading original design manufacturer (ODM) specializing in advanced microfluidic products and laboratory consumables. Our ISO-certified and FDA-registered facilities span 100,000 sq. ft., including approximately 40,000 sq. ft. of high-standard cleanroom space. We provide precision, efficiency, and reliability from prototyping through volume production, serving renowned pharmaceutical and clinical diagnostic companies globally. With a proven track record, HiComp has successfully completed over 100 commercialized projects.
Heron Therapeutics, Inc.
Our mission is to improve the lives of patients by developing novel, best-in-class treatments to address some of the most important unmet patient needs. We aim to develop patient-focused solutions by applying our innovative science and technologies with well-known pharmacology. | Heron’s mission is to improve patient’s lives by developing best-in-class medicines that address major unmet medical needs. We are developing novel, patient-focused solutions that apply our innovative science and technologies to already-approved pharmacological agents.